Corcept Therapeutics Incorporated (CORT)Healthcare | Biotechnology | Redwood City, United States | NasdaqCM
113.37 USD
-2.86
(-2.461%) ⇩
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:21 a.m. EDT
Corcept Therapeutics is riding a massive multi-year wave, having more than decupled over the last nine years with eight profitable years in a row. Fundamentally, the company is firing on all cylinders with 31.7% revenue growth and a clean balance sheet that holds more cash than debt. The valuation gap between the trailing P/E of 269 and the forward P/E of 27.5 tells a clear story: the market expects earnings to explode soon. Technically, the stock is in a confirmed breakout channel, trading well above its 200-day average. The only drawback is the lack of income via dividends and the inherent risk of the biotech sector. This is a pure growth play for investors willing to tolerate volatility for the chance of significant capital appreciation. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.097662 |
| AutoARIMA | 0.119634 |
| AutoETS | 0.189891 |
| MSTL | 0.192978 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 0.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.236 |
| Excess Kurtosis | -1.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.335 |
| Revenue per Share | 7.968 |
| Market Cap | 12,255,116,288 |
| Trailing P/E | 251.93 |
| Forward P/E | 25.74 |
| Beta | 0.40 |
| Profit Margins | 6.64% |
| Website | https://www.corcept.com |
As of Oct. 10, 2026, 2:21 a.m. EDT: Implied volatility remains elevated between 49% and 65% across expirations, signaling uncertainty. Open interest clusters suggest a bullish bias on longer-dated calls (140-155 strikes in Jan 2027) while near-term traders are hedging with significant put open interest at 100-110 strikes. The mix indicates a speculative stance favoring upside potential despite downside protection.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.44071674 |
| Address1 | 101 Redwood Shores Parkway |
| All Time High | 126.38 |
| All Time Low | 0.68 |
| Ask | 127.45 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 692,480 |
| Average Daily Volume3 Month | 1,250,040 |
| Average Volume | 1,250,040 |
| Average Volume10Days | 692,480 |
| Beta | 0.401 |
| Bid | 111.0 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 6.54 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 113.37 |
| Current Ratio | 2.859 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 116.71 |
| Day Low | 113.0201 |
| Debt To Equity | 1.335 |
| Display Name | Corcept Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,358,800 |
| Earnings Call Timestamp Start | 1,785,358,800 |
| Earnings Growth | 0.241 |
| Earnings Quarterly Growth | 0.223 |
| Earnings Timestamp | 1,785,355,200 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | 8,084,000 |
| Ebitda Margins | 0.00973 |
| Enterprise To Ebitda | 1,479.013 |
| Enterprise To Revenue | 14.391 |
| Enterprise Value | 11,956,339,712 |
| Eps Current Year | 2.12 |
| Eps Forward | 4.405 |
| Eps Trailing Twelve Months | 0.45 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 115.5946 |
| Fifty Day Average Change | -2.224594 |
| Fifty Day Average Change Percent | -0.019244794 |
| Fifty Two Week Change Percent | 44.071674 |
| Fifty Two Week High | 126.38 |
| Fifty Two Week High Change | -13.0099945 |
| Fifty Two Week High Change Percent | -0.102943465 |
| Fifty Two Week Low | 28.66 |
| Fifty Two Week Low Change | 84.71001 |
| Fifty Two Week Low Change Percent | 2.9556875 |
| Fifty Two Week Range | 28.66 - 126.38 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,081,949,400,000 |
| Float Shares | 96,475,657 |
| Forward Eps | 4.405 |
| Forward P E | 25.736662 |
| Free Cashflow | 77,395,128 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 730 |
| Fullday Change | 0.62999725 |
| Fullday Change Percent | 0.5557001 |
| Fullday Price | 114.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.98305 |
| Gross Profits | 816,728,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11465 |
| Held Percent Institutions | 0.76924 |
| Implied Shares Outstanding | 108,098,397 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California. |
| Long Name | Corcept Therapeutics Incorporated |
| Market | us_market |
| Market Cap | 12,255,116,288 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1423826 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 54,270,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,192,418,197 |
| Number Of Analyst Opinions | 5 |
| Open | 116.35 |
| Operating Cashflow | 109,700,000 |
| Operating Margins | 0.16124001 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.81 |
| Phone | 650 327 3270 |
| Pre Market Change | 0.62999725 |
| Pre Market Change Percent | 0.5557001 |
| Pre Market Price | 114.0 |
| Pre Market Time | 1,792,149,233 |
| Previous Close | 116.23 |
| Price Eps Current Year | 53.476418 |
| Price Hint | 2 |
| Price To Book | 17.334864 |
| Price To Sales Trailing12 Months | 14.7507515 |
| Profit Margins | 0.066420004 |
| Quick Ratio | 2.504 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | -2.86 |
| Regular Market Change Percent | -2.46064 |
| Regular Market Day High | 116.71 |
| Regular Market Day Low | 113.0201 |
| Regular Market Day Range | 113.0201 - 116.71 |
| Regular Market Open | 116.35 |
| Regular Market Previous Close | 116.23 |
| Regular Market Price | 113.37 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 668,407 |
| Return On Assets | 0.0047400002 |
| Return On Equity | 0.08226 |
| Revenue Growth | 0.317 |
| Revenue Per Share | 7.968 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 108,098,397 |
| Shares Percent Shares Out | 0.079 |
| Shares Short | 8,540,393 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,399,154 |
| Short Name | Corcept Therapeutics Incorporat |
| Short Percent Of Float | 0.1018 |
| Short Ratio | 5.11 |
| Source Interval | 15 |
| State | CA |
| Symbol | CORT |
| Target High Price | 165.0 |
| Target Low Price | 50.0 |
| Target Mean Price | 141.0 |
| Target Median Price | 164.0 |
| Total Cash | 308,196,992 |
| Total Cash Per Share | 2.851 |
| Total Debt | 9,421,000 |
| Total Revenue | 830,812,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.45 |
| Trailing P E | 251.93335 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 71.5621 |
| Two Hundred Day Average Change | 41.8079 |
| Two Hundred Day Average Change Percent | 0.58421844 |
| Type Disp | Equity |
| Volume | 668,407 |
| Website | https://www.corcept.com |
| Zip | 94,065 |